Polaris Group

Equities

6550

KYG7171A1085

Biotechnology & Medical Research

End-of-day quote Taiwan S.E. Other stock markets 2026-02-06			5-day change	1st Jan Change
30.00 ^TWD	-3.54%		-3.23%	-3.54%

Dec. 26	Polaris Group Announces Management Changes, Effective December 26, 2025	CI
Dec. 26	Polaris Group Announces Chief Executive Officer Changes, Effective December 26, 2025	CI

Polaris Group Announces Chief Executive Officer Changes, Effective December 26, 2025

Published on 12/26/2025 at 07:13 am EST

S&P Capital IQ

POLARIS GROUP

-3.54%

Polaris Group announced that Jaan-Pyng Hsu, former Chairman and CEO of the Company, has been replaced by Samuel Chen, Chairman of the Company, as the new Chief Executive Officer due to organizational adjustment. The effective date of the change is December 26, 2025.

Latest news about Polaris Group

Dec. 26	Polaris Group Announces Management Changes, Effective December 26, 2025	CI
Dec. 26	Polaris Group Announces Chief Executive Officer Changes, Effective December 26, 2025	CI
Dec. 25	Polaris Group announced that it expects to receive TWD 3.2 billion in funding	CI
Dec. 16	Polaris Group's CEO Resigns	MT
Dec. 16	Polaris Group Announces Resignation of Steve J.P. Hsu as Chief Executive Officer, Effective December 24, 2025	CI
Dec. 16	Polaris Group Names New Chairman; Shares Rally 10%	MT
Dec. 15	Polaris Group Announces Management Changes, Effective December 24, 2025	CI
Nov. 12	Polaris Group Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-09-01	Polaris Group Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-19	Polaris Cancer Drug Candidate Enters FDA Substantive Review	MT
25-07-21	Polaris Unit Grants Drug Distribution Rights to Bioprofarma Bago	MT
25-06-11	Polaris Group Completes Submission of US FDA Application for Rare Lung Cancer Drug	MT
25-06-10	Polaris Group Completes Rolling Submission of Biologic License Application for ADI-PEG 20 with FDA to Treat Malignant Pleural Mesothelioma	CI
25-05-13	Polaris Group Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-25	Polaris Group Announces Changes in the Board of Directors on Behalf of Key Subsidiary Designerx Pharmaceuticals, Inc	CI
25-04-25	Polaris Group Announces Changes in the Board of Directors on Behalf of Key Subsidiary DRx Pharmaceuticals, Inc	CI
25-04-25	Polaris Group Announces Changes in Designated and Non-Designated Representatives, Effective April 25, 2025	CI
25-04-15	Polaris Unit Signs Two Sales Deals for Malignant Pleural Mesothelioma Drug	MT
25-04-09	Polaris' Taps CEO as Chairman	MT
25-04-08	Polaris Group Announces Chairman Changes	CI
25-03-18	Polaris Group Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-03-17	Polaris Group Books NT$2.6 Billion Loss in 2024	MT
25-03-13	Po Group Announces Change of Representative Director	CI
25-02-19	Ruihua Pharmaceutical (Hong Kong) Co., Ltd. announced that it expects to receive $20 million in funding from Polaris Group	CI
25-01-24	Polaris Group Announces the Resignation of Joey Yen as Financial Officer, Accounting Officer and Corporate Governance Officer	CI

Chart Polaris Group

Duration

Period

6550: Dynamic Chart

Company Profile

The Polaris Group, LLC is a Cayman Islands-based company, which is primarily engaged in biotechnology services, drug testing, contract development and manufacturing services and research, development, manufacture and sales of new drugs. The Companyâ€™s core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.

Employees

Sector

Biotechnology & Medical Research

Calendar

Mar. 12 - Q4 2025 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data